EU/3/04/224: Orphan designation for the treatment of chronic myeloid leukaemia


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2016 on request of the Sponsor.

On 2 September 2004, orphan designation (EU/3/04/224) was granted by the European Commission to Stragen France SAS, France, for homoharringtonine for the treatment of chronic myeloid leukaemia.

The sponsorship was transferred to ChemGenex Europe SAS, France, in January 2009 and subsequently to Teva Pharma GmbH, Germany, in December 2012.

Key facts

Active substance
Intended use
Treatment of chronic myeloid leukaemia
Orphan designation status
EU designation number
Date of designation
Teva Pharma GmbH
Graf-Arco-Str. 3
89079 Ulm
Tel. +49 6105 97 676 17
Fax +49 6105 97 767 60

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating